On November 12, 2020, ICER released its Draft Evidence Report entitled, “Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value.” Patients Rising Now submitted comments on the draft report, raising concerns on a number of fronts. For example, the report includes extremely limited information about quality of life for patients, and the model used to arrive at the report’s projections is extremely complicated and uses too many assumptions. Patients Rising Now is concerned that the draft report could lead to restricted access to treatments for patients. To read Patients Rising Now’s full comments, click here.
Terry Wilcox, Co-Founder and Executive Director
Patients Rising Now